Halozyme Therapeutics Inc Sustainability Reports
Halozyme Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes disruptive drug delivery technology solutions, primarily utilizing its patented recombinant human hyaluronidase enzyme. Its platform enables the subcutaneous delivery of injectable biologics and other therapeutic molecules to improve patient experiences and outcomes.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 529900242I3SV9AGM753
FIGI: BBG001SGX585
20 reports from 2008 to 2025
